Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Phase 2
Recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: GHZ339Drug: Placebo
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT06947993
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
Phase 4
Not yet recruiting
- Conditions
- Coronary Heart Disease
- Interventions
- Combination Product: Standard of Care
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1590
- Registration Number
- NCT06941792
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Phase 3
Not yet recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT06934967
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT06931691
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2883
- Registration Number
- NCT06930859
A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life
Completed
- Conditions
- Familial Mediterranean Fever
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT06923124
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
DFT383 in Pediatric Participants With Nephropathic Cystinosis
Phase 1
Recruiting
- Conditions
- Nephropathic Cystinosis
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT06910813
- Locations
- 🇺🇸
Emory University School of Medicine-Children's Healthcare of Atlanta (recuiting Cohort 0), Atlanta, Georgia, United States
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT06905327
- Locations
- 🇳🇿
Novartis Investigative Site, Auckland, New Zealand
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT06905301
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT06905288
- Locations
- 🇰🇷
Novartis Investigative Site, Busan, Korea, Republic of